Healthcare

Alvotech (NASDAQ: ALVO) shares closed up 19% at $5.27 as BofA Securities initiated coverage on the biosimilar specialist with a Buy rating and a $7 price target.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares fell 9% to $5.66 after the company reported a Q2 net loss of $2.27 million on $0.02 million in revenue.

NewcelX filed a resale prospectus covering up to 694,000 shares held by selling stockholders following its July private placement.

REGENXBIO Inc. (NASDAQ: RGNX) shares fell 25% to $8.06 after an FDA clinical hold on RGX-121 for MPS II, caused by asymptomatic spinal MRI findings in five CAMPSIITE participants, delayed its BLA resubmission.

Autonomix Medical, Inc. (NASDAQ: AMIX) is set to receive U.S. Patent No. 12,714,780, encompassing specialized systems and methods designed to regulate the growth, function, and development of organs and tumors.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) reported a slightly deeper Q2 net loss of $2.27 million on revenue of $0.02 million.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares closed up 8% at $6.80 after the FDA pushed the Deramiocel PDUFA date for DMD to November 22, 2026, a three-month extension following the submission of a major BLA amendment containing long-term HOPE-3 extension data.